Estimate the Relationship Between CXCR4-SDF-1 Axis and Inhibitory Molecules (CTLA4 and PD-1) in Patients with Colon Cancer

Overview

Journal Narra J

Date 2025 Jan 16

PMID 39816054

Authors

Suhad D Abdul-Huseen

Hazima M Alabassi

Affiliations

Soon will be listed here.

Abstract

Colon neoplasia is one of the major malignancies in industrialized countries due to their Western-style food habits. It accounts for more than 50% of the population developing adenomatous polyps by the age of 70 years, but 10% of cancers in developed countries. The aim of this study was to evaluate the pathological role of the C-X-C chemokine receptor type 4/stromal-derived factor 1 axis (CXCR4-SDF-1 axis), and the inhibitory molecules PD-1 and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) in postoperative colon cancer patients undergoing treatment with chemotherapy (oxaliplatin and capecitabine) and estimate the correlation between these studied factors to deeply understand the basic mechanisms and potential diagnostic or therapeutic effects. The study involved 90 patients, including 50 colon cancer patients (male and female, aged 35-65) diagnosed by oncologists at Al-Ramadi Hospital, Ramadi, Iraq. All patients underwent surgical resection and received four cycles of chemotherapy with oxaliplatin (85 mg every 21 days) and capecitabine (6 grams daily for 21 days). Additionally, 40 age- and sex-matched individuals served as the control group. For each participant, CXCR4 and SDF-1 levels were measured using ELISA and the gene expression of and were measured using RT-PCR. The colon cancer patient group showed significantly lower levels of CXCR4 and SDF-1 compared to control groups (0.163±0.012 vs 0.376±0.025 pg/mL and 0.376±0.025 vs 0.699±0.110 pg/mL, respectively, both had =0.001). Moreover, the colon cancer patient group had significantly lower expression of and compared to control group (0.102±0.029-fold vs 1.199±0.391-fold, =0.02; and 0.302±0.140-fold vs 1.441±0.334-fold, =0.008, respectively). In conclusion, the results suggest that CXCR4 and SDF-1 appear promising as diagnostic markers for distinguishing colon cancer patients from healthy conditions.

References

Law A, Valdes-Mora F, Gallego-Ortega D . Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. Cells. 2020; 9(3). PMC: 7140518. DOI: 10.3390/cells9030561. View

DAlterio C, Zannetti A, Trotta A, Ierano C, Napolitano M, Rea G . New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer. Cancers (Basel). 2020; 12(7). PMC: 7409147. DOI: 10.3390/cancers12071952. View

Konya C, Paz Z, Apostolidis S, Tsokos G . Update on the role of Interleukin 17 in rheumatologic autoimmune diseases. Cytokine. 2015; 75(2):207-15. DOI: 10.1016/j.cyto.2015.01.003. View

Dimova I, Karthik S, Makanya A, Hlushchuk R, Semela D, Volarevic V . SDF-1/CXCR4 signalling is involved in blood vessel growth and remodelling by intussusception. J Cell Mol Med. 2019; 23(6):3916-3926. PMC: 6533523. DOI: 10.1111/jcmm.14269. View

Alouche N, Bonaud A, Rondeau V, Hussein-Agha R, Nguyen J, Bisio V . Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to uncontrolled extrafollicular immune response. Blood. 2021; 137(22):3050-3063. PMC: 8176768. DOI: 10.1182/blood.2020007450. View

Korbecki J, Kojder K, Kapczuk P, Kupnicka P, Gawronska-Szklarz B, Gutowska I . The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature. Int J Mol Sci. 2021; 22(2). PMC: 7830156. DOI: 10.3390/ijms22020843. View

Diaz-Barreiro A, Huard A, Palmer G . Multifaceted roles of IL-38 in inflammation and cancer. Cytokine. 2022; 151:155808. DOI: 10.1016/j.cyto.2022.155808. View

Goita A, Guenot D . Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7. Cancers (Basel). 2022; 14(7). PMC: 8997717. DOI: 10.3390/cancers14071810. View

Zhao Q, Long Y, Cheng W, Huang Y, Li J, Li Y . Visfatin inhibits colon cancer cell apoptosis and decreases chemosensitivity to 5‑FU by promoting the SDF‑1/CXCR4/Akt axis. Int J Oncol. 2022; 60(6). PMC: 9083850. DOI: 10.3892/ijo.2022.5365. View

10.

Jiang K, Li J, Zhang J, Wang L, Zhang Q, Ge J . SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy. Int Immunopharmacol. 2019; 75:105818. DOI: 10.1016/j.intimp.2019.105818. View

11.

Bedri S, Sultan A, Alkhalaf M, Moustafa A, Vranic S . Epstein-Barr virus (EBV) status in colorectal cancer: a mini review. Hum Vaccin Immunother. 2018; 15(3):603-610. PMC: 6605740. DOI: 10.1080/21645515.2018.1543525. View

12.

Feng W, Huang W, Chen J, Qiao C, Liu D, Ji X . CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3. Theranostics. 2021; 11(6):2612-2633. PMC: 7806482. DOI: 10.7150/thno.52199. View

13.

Boutet M, Bart G, Penhoat M, Amiaud J, Brulin B, Charrier C . Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin Exp Immunol. 2015; 184(2):159-73. PMC: 4837235. DOI: 10.1111/cei.12761. View

14.

Arango Duque G, Descoteaux A . Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014; 5:491. PMC: 4188125. DOI: 10.3389/fimmu.2014.00491. View

15.

Kinzler K, Vogelstein B . Lessons from hereditary colorectal cancer. Cell. 1996; 87(2):159-70. DOI: 10.1016/s0092-8674(00)81333-1. View

16.

Fang Y, Lyu F, Abuwala N, Tal A, Chen A, Taylor H . Chemokine C-X-C receptor 4 mediates recruitment of bone marrow-derived nonhematopoietic and immune cells to the pregnant uterus†. Biol Reprod. 2022; 106(6):1083-1097. PMC: 9198949. DOI: 10.1093/biolre/ioac029. View

17.

Biasci D, Smoragiewicz M, Connell C, Wang Z, Gao Y, Thaventhiran J . CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci U S A. 2020; 117(46):28960-28970. PMC: 7682333. DOI: 10.1073/pnas.2013644117. View

18.

Benson 3rd A, Venook A, Cederquist L, Chan E, Chen Y, Cooper H . Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(3):370-398. DOI: 10.6004/jnccn.2017.0036. View

19.

Feig C, Jones J, Kraman M, Wells R, Deonarine A, Chan D . Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(50):20212-7. PMC: 3864274. DOI: 10.1073/pnas.1320318110. View

20.

Mousavi A . CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy. Immunol Lett. 2019; 217:91-115. DOI: 10.1016/j.imlet.2019.11.007. View